[DEF 14A] Unity Biotechnology, Inc. Definitive Proxy Statement
Unity Biotechnology, Inc. (UBX) is asking stockholders to approve a Plan of Complete Liquidation and Dissolution at a virtual Special Meeting on September 18, 2025 to authorize the Board to wind down the company. Only holders of record as of July 25, 2025 may vote; as of that date there were 17,212,172 shares of Common Stock outstanding and one share of Series A Preferred Stock that carries 600,000,000 votes and will vote in proportion to Common Stock votes on the Dissolution Proposal. The Board unanimously recommends a vote "FOR" the Dissolution and Adjournment proposals.
The Board approved the Dissolution and Plan of Dissolution on June 27, 2025, concurrently accepting the resignations of the CEO, CFO and CLO and reducing the Board from eight directors to one, appointing Craig R. Jalbert to lead the wind-down. The company ceased clinical development and expects to use remaining cash to pay winding-up costs first; based on information available at the time of this proxy statement, the Board expects there will not be any amounts available for distribution to stockholders. The company also disclosed its Common Stock was suspended from Nasdaq on July 9, 2025 and has been trading on the OTC Markets.
Unity Biotechnology, Inc. (UBX) chiede agli azionisti di approvare un Piano di Liquidazione e Scioglimento Completo in una riunione speciale virtuale il 18 settembre 2025 per autorizzare il Consiglio di Amministrazione ad avviare la liquidazione della società. Potranno votare solo i titolari registrati alla data del 25 luglio 2025; a quella data risultavano in circolazione 17,212,172 azioni ordinarie e una azione di Serie A Preferred che attribuisce 600,000,000 voti e voterà in proporzione ai voti delle azioni ordinarie sulla proposta di scioglimento. Il Consiglio raccomanda all'unanimità di votare "A FAVORE" delle proposte di Scioglimento e di Rinvio.
Il Consiglio ha approvato lo Scioglimento e il Piano di Scioglimento il 27 giugno 2025, accettando contestualmente le dimissioni del CEO, del CFO e del CLO e riducendo il numero dei membri da otto a uno, nominando Craig R. Jalbert per guidare la fase di liquidazione. La società ha interrotto lo sviluppo clinico e prevede di utilizzare la liquidità residua per coprire prioritariamente i costi di liquidazione; in base alle informazioni disponibili al momento di questo prospetto per delega, il Consiglio ritiene che non ci saranno somme disponibili da distribuire agli azionisti. La società ha inoltre comunicato che le sue azioni ordinarie sono state sospese dal Nasdaq il 9 luglio 2025 e sono state negoziate sui mercati OTC.
Unity Biotechnology, Inc. (UBX) solicita a los accionistas aprobar un Plan de Liquidación y Disolución Completa en una Junta Especial virtual el 18 de septiembre de 2025 para autorizar al Consejo de Administración a proceder con el cierre de la compañía. Solo podrán votar los titulares registrados a fecha del 25 de julio de 2025; a esa fecha había 17,212,172 acciones ordinarias en circulación y una acción de la Serie A Preferred que ostenta 600,000,000 votos y votará en proporción a los votos de las acciones ordinarias sobre la Propuesta de Disolución. El Consejo recomienda por unanimidad votar "A FAVOR" las propuestas de Disolución y Aplazamiento.
El Consejo aprobó la Disolución y el Plan de Disolución el 27 de junio de 2025, aceptando simultáneamente las renuncias del CEO, del CFO y del CLO y reduciendo el Consejo de ocho miembros a uno, nombrando a Craig R. Jalbert para dirigir el cierre. La compañía ha cesado el desarrollo clínico y prevé utilizar el efectivo restante para pagar en primer lugar los costes de liquidación; conforme a la información disponible en el momento de este folleto, el Consejo estima que no habrá montos disponibles para distribuir a los accionistas. La compañía también informó que sus acciones ordinarias fueron suspendidas en Nasdaq el 9 de julio de 2025 y desde entonces se han negociado en los mercados OTC.
Unity Biotechnology, Inc. (UBX)는 주주들에게 가상 특별총회에서 2025년 9월 18일에 완전 청산 및 해산 계획(Plan of Complete Liquidation and Dissolution)을 승인해 이사회가 회사를 정리할 수 있도록 해 줄 것을 요청하고 있습니다. 투표권은 2025년 7월 25일 현재 등기된 주주에게만 부여됩니다; 해당 일자 기준으로 보통주가 17,212,172주 발행되어 있었고, 보통주 투표수에 비례해 투표할 권리를 가진 시리즈 A 우선주 1주가 600,000,000표를 보유하고 있습니다. 이사회는 해산 및 산회(Adjournment) 안건에 대해 만장일치로 "찬성"을 권고합니다.
이사회는 2025년 6월 27일에 해산 및 해산 계획을 승인하고 동시에 CEO, CFO 및 CLO의 사임을 수리했으며 이사회를 8인에서 1인으로 축소하고 청산 작업을 이끌도록 Craig R. Jalbert를 임명했습니다. 회사는 임상 개발을 중단했으며 남은 현금은 우선적으로 청산 비용을 지불하는 데 사용할 예정입니다; 이 위임장 시점의 정보에 따르면 이사회는 주주에게 분배할 수 있는 금액이 없을 것으로 예상합니다. 또한 회사는 보통주가 2025년 7월 9일에 나스닥에서 거래 정지되었으며 이후 OTC 마켓에서 거래되고 있다고 공시했습니다.
Unity Biotechnology, Inc. (UBX) demande aux actionnaires d'approuver un Plan de liquidation complète et de dissolution lors d'une assemblée extraordinaire virtuelle le 18 septembre 2025 afin d'autoriser le conseil d'administration à procéder à la mise en liquidation de la société. Seuls les titulaires inscrits au registre au 25 juillet 2025 peuvent voter ; à cette date, 17,212,172 actions ordinaires étaient en circulation et une action de la Série A Preferred détient 600,000,000 voix et votera proportionnellement aux voix des actions ordinaires sur la proposition de dissolution. Le conseil recommande à l'unanimité de voter « POUR » les propositions de dissolution et d'ajournement.
Le conseil a approuvé la dissolution et le plan de dissolution le 27 juin 2025, acceptant simultanément les démissions du CEO, du CFO et du CLO, réduisant le conseil de huit administrateurs à un seul et nommant Craig R. Jalbert pour superviser la liquidation. La société a cessé son développement clinique et prévoit d'utiliser la trésorerie restante pour couvrir en priorité les coûts de liquidation ; d'après les informations disponibles au moment de ce proxy, le conseil s'attend à ce qu'aucun montant ne soit disponible pour être distribué aux actionnaires. La société a également indiqué que ses actions ordinaires ont été suspendues du Nasdaq le 9 juillet 2025 et sont depuis négociées sur les marchés OTC.
Unity Biotechnology, Inc. (UBX) bittet die Aktionäre, auf einer virtuellen außerordentlichen Hauptversammlung am 18. September 2025 einen Plan zur vollständigen Liquidation und Auflösung zu genehmigen, um den Verwaltungsrat zu bevollmächtigen, das Unternehmen abzuwickeln. Abstimmungsberechtigt sind nur im Register eingetragene Inhaber zum 25. Juli 2025; an diesem Datum waren 17,212,172 Stammaktien ausgegeben und eine Aktie der Serie A Preferred, die 600,000,000 Stimmen trägt und bei der Abstimmung über den Auflösungsantrag proportional zu den Stimmen der Stammaktien stimmen wird. Der Verwaltungsrat empfiehlt einstimmig ein "FÜR"-Votum für die Anträge auf Auflösung und Vertagung.
Der Verwaltungsrat genehmigte die Auflösung und den Auflösungsplan am 27. Juni 2025, akzeptierte gleichzeitig die Rücktritte des CEO, CFO und CLO und reduzierte den Vorstand von acht auf einen Direktor und ernannte Craig R. Jalbert zur Leitung der Abwicklung. Das Unternehmen hat die klinische Entwicklung eingestellt und beabsichtigt, vorhandene Mittel vorrangig zur Begleichung der Abwicklungskosten zu verwenden; nach den zum Zeitpunkt dieses Proxy-Statements verfügbaren Informationen erwartet der Verwaltungsrat, dass keine Mittel zur Ausschüttung an die Aktionäre zur Verfügung stehen werden. Das Unternehmen teilte außerdem mit, dass seine Stammaktien am 9. Juli 2025 vom Nasdaq ausgesetzt wurden und inzwischen am OTC-Markt gehandelt werden.
- Board unanimity: The Board unanimously recommends a vote "FOR" the Dissolution and Adjournment proposals.
- Experienced wind-down lead: Craig R. Jalbert was appointed President and director and is described as having decades of experience with distressed businesses and wind downs.
- Clear timeline and procedures: Proxy discloses Record Date (July 25, 2025), Special Meeting date (September 18, 2025), and detailed Delaware dissolution procedures to be followed.
- Plan to dissolve the company: Board adopted a Plan of Dissolution and is seeking shareholder approval to liquidate operations.
- Expected no distributions: The proxy states that, based on information currently available, the Board expects there will not be any amounts available for distribution to stockholders.
- Ceased clinical development and workforce reductions: The company ceased clinical development and implemented reductions and consulting arrangements as part of the wind-down.
- Management and board resignations: CEO, CFO and CLO ceased roles and the board was reduced from eight directors to one on June 27, 2025.
- Delisting event: Common Stock was suspended from Nasdaq on July 9, 2025 and is trading on the OTC Markets.
- Stock transfer suspension: If the Board proceeds, stock transfer books will be closed and further transfers will not be recorded after the Effective Time.
Insights
TL;DR: The company seeks shareholder approval to dissolve; current disclosures indicate little or no residual value for equity holders.
The Board adopted a Plan of Dissolution and recommends shareholder approval, while noting the Board retains sole discretion on timing and may abandon the plan prior to filing the Certificate of Dissolution. Key numeric facts include 17,212,172 outstanding Common shares, a Record Date of July 25, 2025, and a Special Meeting on September 18, 2025. The proxy states the Company will prioritize payment of taxes, claims, lease obligations, insurance, professional fees and reserves before any liquidating distributions and explicitly states that, based on currently available information, there will not be any amounts available for distribution. These facts signal a materially adverse outcome for common stockholders and high uncertainty on timing and magnitude of any recovery.
TL;DR: Governance concentrated during wind-down; Board reduced to one director and a Series A preferred share was issued to mirror shareholder votes.
Effective June 27, 2025, the CEO, CFO and CLO resigned and all serving directors resigned, reducing the Board to one Class I director, Craig R. Jalbert, who was appointed President and Corporate Secretary and has extensive experience with distressed wind-downs per the proxy. The Company issued a single share of Series A Preferred Stock (one share) that holds 600,000,000 votes and will be voted in proportion to Common Stock votes to "amplify" the expressed will of voting stockholders at the Special Meeting. These steps centralize control for an orderly wind-down but raise governance concentration and potential conflicts of interest concerns; however, the proxy discloses the arrangements and Mr. Jalbert's background in distressed situations.
Unity Biotechnology, Inc. (UBX) chiede agli azionisti di approvare un Piano di Liquidazione e Scioglimento Completo in una riunione speciale virtuale il 18 settembre 2025 per autorizzare il Consiglio di Amministrazione ad avviare la liquidazione della società. Potranno votare solo i titolari registrati alla data del 25 luglio 2025; a quella data risultavano in circolazione 17,212,172 azioni ordinarie e una azione di Serie A Preferred che attribuisce 600,000,000 voti e voterà in proporzione ai voti delle azioni ordinarie sulla proposta di scioglimento. Il Consiglio raccomanda all'unanimità di votare "A FAVORE" delle proposte di Scioglimento e di Rinvio.
Il Consiglio ha approvato lo Scioglimento e il Piano di Scioglimento il 27 giugno 2025, accettando contestualmente le dimissioni del CEO, del CFO e del CLO e riducendo il numero dei membri da otto a uno, nominando Craig R. Jalbert per guidare la fase di liquidazione. La società ha interrotto lo sviluppo clinico e prevede di utilizzare la liquidità residua per coprire prioritariamente i costi di liquidazione; in base alle informazioni disponibili al momento di questo prospetto per delega, il Consiglio ritiene che non ci saranno somme disponibili da distribuire agli azionisti. La società ha inoltre comunicato che le sue azioni ordinarie sono state sospese dal Nasdaq il 9 luglio 2025 e sono state negoziate sui mercati OTC.
Unity Biotechnology, Inc. (UBX) solicita a los accionistas aprobar un Plan de Liquidación y Disolución Completa en una Junta Especial virtual el 18 de septiembre de 2025 para autorizar al Consejo de Administración a proceder con el cierre de la compañía. Solo podrán votar los titulares registrados a fecha del 25 de julio de 2025; a esa fecha había 17,212,172 acciones ordinarias en circulación y una acción de la Serie A Preferred que ostenta 600,000,000 votos y votará en proporción a los votos de las acciones ordinarias sobre la Propuesta de Disolución. El Consejo recomienda por unanimidad votar "A FAVOR" las propuestas de Disolución y Aplazamiento.
El Consejo aprobó la Disolución y el Plan de Disolución el 27 de junio de 2025, aceptando simultáneamente las renuncias del CEO, del CFO y del CLO y reduciendo el Consejo de ocho miembros a uno, nombrando a Craig R. Jalbert para dirigir el cierre. La compañía ha cesado el desarrollo clínico y prevé utilizar el efectivo restante para pagar en primer lugar los costes de liquidación; conforme a la información disponible en el momento de este folleto, el Consejo estima que no habrá montos disponibles para distribuir a los accionistas. La compañía también informó que sus acciones ordinarias fueron suspendidas en Nasdaq el 9 de julio de 2025 y desde entonces se han negociado en los mercados OTC.
Unity Biotechnology, Inc. (UBX)는 주주들에게 가상 특별총회에서 2025년 9월 18일에 완전 청산 및 해산 계획(Plan of Complete Liquidation and Dissolution)을 승인해 이사회가 회사를 정리할 수 있도록 해 줄 것을 요청하고 있습니다. 투표권은 2025년 7월 25일 현재 등기된 주주에게만 부여됩니다; 해당 일자 기준으로 보통주가 17,212,172주 발행되어 있었고, 보통주 투표수에 비례해 투표할 권리를 가진 시리즈 A 우선주 1주가 600,000,000표를 보유하고 있습니다. 이사회는 해산 및 산회(Adjournment) 안건에 대해 만장일치로 "찬성"을 권고합니다.
이사회는 2025년 6월 27일에 해산 및 해산 계획을 승인하고 동시에 CEO, CFO 및 CLO의 사임을 수리했으며 이사회를 8인에서 1인으로 축소하고 청산 작업을 이끌도록 Craig R. Jalbert를 임명했습니다. 회사는 임상 개발을 중단했으며 남은 현금은 우선적으로 청산 비용을 지불하는 데 사용할 예정입니다; 이 위임장 시점의 정보에 따르면 이사회는 주주에게 분배할 수 있는 금액이 없을 것으로 예상합니다. 또한 회사는 보통주가 2025년 7월 9일에 나스닥에서 거래 정지되었으며 이후 OTC 마켓에서 거래되고 있다고 공시했습니다.
Unity Biotechnology, Inc. (UBX) demande aux actionnaires d'approuver un Plan de liquidation complète et de dissolution lors d'une assemblée extraordinaire virtuelle le 18 septembre 2025 afin d'autoriser le conseil d'administration à procéder à la mise en liquidation de la société. Seuls les titulaires inscrits au registre au 25 juillet 2025 peuvent voter ; à cette date, 17,212,172 actions ordinaires étaient en circulation et une action de la Série A Preferred détient 600,000,000 voix et votera proportionnellement aux voix des actions ordinaires sur la proposition de dissolution. Le conseil recommande à l'unanimité de voter « POUR » les propositions de dissolution et d'ajournement.
Le conseil a approuvé la dissolution et le plan de dissolution le 27 juin 2025, acceptant simultanément les démissions du CEO, du CFO et du CLO, réduisant le conseil de huit administrateurs à un seul et nommant Craig R. Jalbert pour superviser la liquidation. La société a cessé son développement clinique et prévoit d'utiliser la trésorerie restante pour couvrir en priorité les coûts de liquidation ; d'après les informations disponibles au moment de ce proxy, le conseil s'attend à ce qu'aucun montant ne soit disponible pour être distribué aux actionnaires. La société a également indiqué que ses actions ordinaires ont été suspendues du Nasdaq le 9 juillet 2025 et sont depuis négociées sur les marchés OTC.
Unity Biotechnology, Inc. (UBX) bittet die Aktionäre, auf einer virtuellen außerordentlichen Hauptversammlung am 18. September 2025 einen Plan zur vollständigen Liquidation und Auflösung zu genehmigen, um den Verwaltungsrat zu bevollmächtigen, das Unternehmen abzuwickeln. Abstimmungsberechtigt sind nur im Register eingetragene Inhaber zum 25. Juli 2025; an diesem Datum waren 17,212,172 Stammaktien ausgegeben und eine Aktie der Serie A Preferred, die 600,000,000 Stimmen trägt und bei der Abstimmung über den Auflösungsantrag proportional zu den Stimmen der Stammaktien stimmen wird. Der Verwaltungsrat empfiehlt einstimmig ein "FÜR"-Votum für die Anträge auf Auflösung und Vertagung.
Der Verwaltungsrat genehmigte die Auflösung und den Auflösungsplan am 27. Juni 2025, akzeptierte gleichzeitig die Rücktritte des CEO, CFO und CLO und reduzierte den Vorstand von acht auf einen Direktor und ernannte Craig R. Jalbert zur Leitung der Abwicklung. Das Unternehmen hat die klinische Entwicklung eingestellt und beabsichtigt, vorhandene Mittel vorrangig zur Begleichung der Abwicklungskosten zu verwenden; nach den zum Zeitpunkt dieses Proxy-Statements verfügbaren Informationen erwartet der Verwaltungsrat, dass keine Mittel zur Ausschüttung an die Aktionäre zur Verfügung stehen werden. Das Unternehmen teilte außerdem mit, dass seine Stammaktien am 9. Juli 2025 vom Nasdaq ausgesetzt wurden und inzwischen am OTC-Markt gehandelt werden.
TABLE OF CONTENTS
☐ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☒ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material under §240.14a-12 |
☒ | No fee required. |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
TABLE OF CONTENTS
Sincerely, | |||
/s/ Craig R. Jalbert | |||
Craig R. Jalbert | |||
President and Secretary | |||
August 11, 2025 | |||
TABLE OF CONTENTS
Time and Date | September 18, 2025 at 9:00 a.m. Pacific Time | ||
Place | The special meeting of stockholders (the “Special Meeting”) of Unity Biotechnology, Inc. (“Unity,” the “Company,” “we,” “us” and “our”) will be held in a virtual format only at www.virtualshareholdermeeting.com/UBX2025SM. | ||
Items of Business | The approval of the liquidation and dissolution of the Company (the “Dissolution”) and the Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”), attached hereto as Exhibit A, which, if approved, will authorize the Board to liquidate and dissolve the Company in accordance with the Plan of Dissolution (the “Dissolution Proposal”). To approve one or more adjournments of the Special Meeting, from time to time, to a later date or dates, even if a quorum is present, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve the Dissolution Proposal (the “Adjournment Proposal”). | ||
Board Recommendations | After careful consideration of a number of factors, as described in the attached proxy statement, the Board has unanimously determined that the Dissolution Proposal and Adjournment Proposal are advisable and in the best interests of Unity and its stockholders. The Board unanimously recommends that you vote “FOR” each of the Dissolution Proposal and the Adjournment Proposal. | ||
Record Date | The close of business on July 25, 2025 (the “Record Date”). Only holders of our common stock, par value $0.0001 per share (“Common Stock”), and of our outstanding share of Series A Preferred Stock, par value $0.0001 per share, on the Record Date are entitled to receive notice of, and to vote at, the Special Meeting, or any adjournment thereof. The share of Series A Preferred Stock may only vote on the Dissolution Proposal. | ||
TABLE OF CONTENTS
Proxy Voting | IMPORTANT Please vote your shares at your earliest convenience by completing, signing, dating and returning your proxy card or by Internet or telephone voting as described on your proxy card. This will save the expense and extra work of additional solicitation. Submitting your proxy now will not prevent you from voting your shares at the Special Meeting, as your proxy is revocable at your option. | ||
TABLE OF CONTENTS
Page | |||
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 1 | ||
WEBSITES | 2 | ||
RISK FACTORS | 3 | ||
QUESTIONS AND ANSWERS REGARDING THIS SOLICITATION AND VOTING AT THE SPECIAL MEETING | 7 | ||
PROPOSAL 1: APPROVAL OF THE DISSOLUTION PURSUANT TO THE PLAN OF DISSOLUTION | 14 | ||
CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PROPOSED DISSOLUTION | 25 | ||
PROPOSAL 2: APPROVAL OF ADJOURNMENT OF SPECIAL MEETING TO SOLICIT ADDITIONAL PROXIES | 31 | ||
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 32 | ||
WHERE YOU CAN FIND ADDITIONAL INFORMATION | 34 | ||
HOUSEHOLDING | 35 | ||
OTHER MATTERS | 36 | ||
EXHIBIT A | 37 | ||
ANNEX A | A-1 | ||
TABLE OF CONTENTS
• | plans and expectations for the Dissolution; |
• | beliefs about the Company’s available options and financial condition; |
• | all statements regarding the tax and accounting consequences of the transactions contemplated by the Dissolution; and |
• | all statements regarding the amount and timing of distributions made to stockholders, if any, in connection with the Dissolution. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | by Telephone - You can submit a proxy by telephone by calling 800-690-6903 and following the instructions on the proxy card; |
• | by Internet - You can submit a proxy over the Internet at www.proxyvote.com by following the instructions on the proxy card; or |
• | by Mail - You can submit a proxy by mail by signing, dating and mailing the proxy card, which you may have received by mail. |
• | Instructions on how to attend and participate via the Internet, including how to demonstrate proof of stock ownership, are posted at www.virtualshareholdermeeting.com/UBX2025SM. |
• | Assistance with questions regarding how to attend and participate via the Internet will be provided at virtualshareholdermeeting.com/UBX2025SM on the day of the Special Meeting. |
• | Webcast starts at 9:00 a.m. Pacific Time. |
• | You will need your 16-Digit control number to enter the Special Meeting. |
• | Stockholders may submit questions while attending the Special Meeting via the Internet. |
TABLE OF CONTENTS
• | sending a written statement to that effect to the attention of our Corporate Secretary at Unity Biotechnology, Inc., 124 Washington Street, Suite 101, Foxborough, Massachusetts 02035 provided such statement is received no later than September 17, 2025; |
• | submitting another proxy by Internet or telephone at a later time before the closing of those voting facilities at 11:59 p.m., Pacific Time on September 17, 2025; |
• | submitting a properly signed proxy card with a later date that is received no later than September 17, 2025; or |
• | attending the Special Meeting, revoking your proxy and voting during the Special Meeting. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | the payment of income and other taxes; |
• | the payment of the costs associated with our Dissolution and winding up over the Survival Period; these costs may include, among others, expenses necessary to the implementation and administration of our Plan of Dissolution and fees and other amounts payable to professional advisors (including legal counsel, financial advisors and others) and to consultants and others assisting us with our Dissolution; |
• | the payment of any claims by others against us that we do not reject as part of the dissolution process; |
• | the payment of any amounts owed by us under contracts with third parties; |
• | the funding of any reserves or other security that is established to pay for asserted claims (including lawsuits) and possible future claims, as further described below; and |
• | solely to the extent we have cash remaining after provision for the above-described payments and funding of any reserves or other security that is established, liquidating distributions to be made to our stockholders, which distributions may be made from time to time as available and in accordance with the procedures required by the DGCL and the Plan of Dissolution as described below. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | expenses, including retention amounts, incurred in connection with extending our directors’ and officers’ insurance coverage; |
• | expenses incurred in connection with the Dissolution; |
• | taxes imposed upon us and any of our assets; and |
• | professional, legal, consulting and accounting fees. |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | banks, financial institutions, or insurance companies; |
• | tax-exempt organizations or governmental organizations; |
• | persons who hold shares of our Common Stock as part of a straddle, hedge, integrated transaction, or conversion transaction; |
• | U.S. expatriates and former citizens or long-term residents of the United States; |
• | persons holding shares through a partnership or other fiscally transparent entity; |
• | persons deemed to sell our common stock under the constructive sale provisions of the Code; |
• | brokers, dealers, or traders in securities, commodities. or currencies, or other persons who have elected mark-to-market accounting; |
• | U.S. Holders whose “functional currency” is not the U.S. dollar; |
• | regulated investment companies or real estate investment trusts; |
• | stockholders who received shares of our Common Stock through the exercise of incentive stock options or through the issuance of restricted stock under an equity incentive plan or otherwise as compensation; |
• | persons for whom our Common Stock constitutes “qualified small business stock” under Section 1202 of the Code; |
• | “controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings to avoid U.S. federal income tax; |
• | “qualified foreign pension funds” as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds; |
• | persons subject to special tax accounting rules as a result of any item of gross income with respect to our Common Stock being taken into account in an applicable financial statement; |
• | tax-qualified retirement plans; or |
• | persons who own (directly or through attribution) five percent or more (by voting power or value) of our Common Stock. |
TABLE OF CONTENTS
• | an individual citizen or resident of the United States; |
• | a corporation created or organized in or under the laws of the United States or any state thereof or the District of Columbia; |
• | an estate the income of which is subject to U.S. federal income tax regardless of its source; or |
• | a trust that (1) is subject to the primary supervision of a U.S. court and one or more United States persons (within the meaning of Section 7701(a)(30) of the Code) have authority to control all of the substantial decisions of the trust, or (2) has a valid election in effect to be treated as a United States person. |
TABLE OF CONTENTS
• | the gain is effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable); |
• | the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or |
• | our Common Stock constitutes a U.S. real property interest (“USRPI”) by reason of our status as a U.S. real property holding corporation (“USRPHC”) for U.S. federal income tax purposes. |
TABLE OF CONTENTS
• | the holder fails to furnish the holder’s taxpayer identification number, which for an individual is ordinarily his or her social security number; |
• | the holder furnishes an incorrect taxpayer identification number; |
• | the applicable withholding agent is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or |
• | the holder fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Shares of Common Stock Beneficially Owned | ||||||||||||
Name of Beneficial Owner | Common Stock | Number of Shares Exercisable Within 60 Days | Number of Shares Beneficially Owned | Percentage of Shares Beneficially Owned | ||||||||
5% and Greater Stockholders: | ||||||||||||
Entities Associated with Alyeska Investment Group, L.P.(1) | 292,091 | 1,586,000 | 1,878,091 | 9.9% | ||||||||
Entities Associated with ARCH Venture Partners(2) | 1,004,817 | — | 1,004,817 | 5.8% | ||||||||
Named Executive Officers and Directors: | ||||||||||||
Anirvan Ghosh, Ph.D.(3) | 138,446 | 719,415 | 857,861 | 4.8% | ||||||||
Lynne Sullivan(4) | 72,295 | 242,583 | 314,878 | 1.8% | ||||||||
Alexander Nguyen(5) | 35,315 | 206,040 | 241,355 | 1.4% | ||||||||
Craig R. Jalbert(6) | — | — | — | * | ||||||||
All directors and executive officers as a group (1 person) | — | — | * | |||||||||
* | Indicates beneficial ownership of less than 1% of the total outstanding common stock. |
(1) | As reported on a Schedule 13G/A filed with the SEC on April 15, 2025. Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh (collectively, “Alyeska”) are the beneficial owners of 1,578,091 shares of common stock, which includes (i) 292,091 shares of common stock, and (ii) warrants to purchase 1,286,000 shares of our common stock, which warrants are subject to a beneficial ownership limitation that precludes Alyeska from exercising any portion of them to the extent that, following the exercise, the Alyeska’s beneficial ownership of common stock would exceed 9.99% of the total number of outstanding shares. The address of Alyeska is 77 West Wacker Drive, 7th Floor, Chicago, Illinois 60601. |
(2) | As reported on a Schedule 13G/A filed with the SEC on February 11, 2022. Consists of (i) 836,576 shares of common stock held by ARCH Venture Fund VII, L.P. (“ARCH VII”), and (ii) 168,241 shares of common stock held by ARCH Venture Fund VIII Overage, L.P. (“ARCH VIII Overage”). ARCH Venture Partners VII, L.P. (“AVP VII LP”), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. AVP VII LP disclaims beneficial ownership of all shares held by ARCH VII in which AVP VII LP does not have an actual pecuniary interest. ARCH Venture Partners VII, LLC (“AVP VII LLC”), as the sole general partner of AVP VII LP, may be deemed to beneficially own the shares held by ARCH VII. AVP VII LLC disclaims beneficial ownership of all shares held by ARCH VII in which AVP VII LLC does not have an actual pecuniary interest. ARCH Venture Partners VIII, LLC (“AVP VIII LLC”), as the sole general partner of ARCH VIII Overage, may be deemed to beneficially own the shares held by ARCH VIII Overage. AVP VIII LLC disclaims beneficial ownership of all shares held by ARCH VIII Overage in which AVP VIII LLC does not have an actual pecuniary interest. As managing directors of AVP VII LP and AVP VIII LLC, each of Keith Crandell, Clinton Bybee, and Robert T. Nelsen (the “ARCH Managing Directors”) may be deemed to share the power to direct the disposition and vote of, and therefore to beneficially own, the shares held by ARCH VII and ARCH VIII Overage. The ARCH Managing Directors disclaim beneficial ownership of all shares held by ARCH VII and ARCH VIII Overage except to the extent of any actual pecuniary interest. The address of ARCH VII, ARCH Overage VIII, AVP VII LP, AVP VII LLC, AVP VIII LLC, and the ARCH Managing Directors is 8755 West Higgins Avenue, Suite 1025, Chicago, Illinois 60631. |
TABLE OF CONTENTS
(3) | Consists of (i) 138,446 shares of common stock, and (ii) 719,415 shares of common stock that may be acquired pursuant to the exercise of stock options within 60 days of the Record Date. Dr. Ghosh departed from the Company on June 27, 2025. The beneficial ownership reported herein is based on information known to the Company as of June 26, 2025. |
(4) | Consists of (i) 72,295 shares of common stock, and (ii) 242,583 shares of common stock that may be acquired pursuant to the exercise of stock options within 60 days of Record Date. Ms. Sullivan departed from the Company on June 27, 2025. The beneficial ownership reported herein is based on information known to the Company as of June 26, 2025. |
(5) | Consists of (i) 35,315 shares of common stock, and (ii) 206,040 shares of common stock that may be acquired pursuant to the exercise of stock options within 60 days of Record Date. Mr. Nguyen departed from the Company on June 27, 2025. The beneficial ownership reported herein is based on information known to the Company as of June 26, 2025. |
(6) | As of the record date for the Special Meeting, Mr. Jalbert owned the one share of Series A Preferred Stock issued and outstanding as of such date. Such share of Series A Preferred Stock is not convertible into common stock and has voting rights as described under “Questions and Answers About These Proxy Materials and Voting—How many votes do I have?” |
TABLE OF CONTENTS
• | our Annual Report on Form 10-K for the year ended December 31, 2024, initially filed with the SEC on March 7, 2025 and amended on April 11, 2025; |
• | our Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the SEC on April 22, 2025; |
• | our Current Reports filed on Form 8-K with the SEC on January 6, 2025, March 10, 2025, March 17, 2025, March 24, 2025, April 4, 2025, May 5, 2025, June 20, 2025, June 30, 2025 and July 22, 2025, as amended. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS

TABLE OF CONTENTS
